DDInter1323 DDInter1628
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Octreotide {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Octreotide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Octreotide {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is downregulated by {v} (Disease) and {u} (Disease) associated with {v} (Gene) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Octreotide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digitoxin
Digitoxin {u} (Compound) downregulates {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Octreotide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digitoxin
Digitoxin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Oxycodone {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digitoxin
Digitoxin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Bromocriptine {u} (Compound) downregulates {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Octreotide (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Octreotide (Compound) binds MPO (Gene) and MPO (Gene) is downregulated by hematologic cancer (Disease) and MPO (Disease) associated with hematologic cancer (Gene) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) downregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Ruxolitinib (Compound)